Direct vascular effects of agents used in the pharmacotherapy of cerebrovascular disease on isolated cerebral vessels.
D000109:Acetylcholine / Q000627:therapeutic use; D000818:Animals; D002415:Cats; D002536:Cerebral Arteries / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000627:therapeutic use; D010208:Papaverine / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D010841:Pia Mater / Q000098:blood supply; D010880:Piperidines / Q000627:therapeutic use; D011188:Potassium / Q000627:therapeutic use; D012701:Serotonin / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014749:Vincamine / Q000627:therapeutic use; D014970:Xanthines / Q000627:therapeutic use
D010880:Piperidines; D014665:Vasodilator Agents; D014970:Xanthines; C008514:methylxanthine; D012701:Serotonin; D014749:Vincamine; D010208:Papaverine; D000109:Acetylcholine; C010739:ifenprodil; D011188:Potassium; D009638:Norepinephrine; D010646:Phentolamine